AGENT Preclinical Research

Boston Scientific has developed a comprehensive PRECLINICAL PROGRAM to provide strong evidence that supports the safety and performance of AGENT™ Paclitaxel Coated-PTCA Balloon Catheter.

Boston Scientific’s Preclinical program for the TransPax™ coating has been ongoing for over 6 years, involved more than 300 animals, and tested the coating on both IC and PI drug-coated balloons (DCB). Ranger™ Paclitaxel-Coated PTA Balloon Catheter is Boston Scientific's DCB for Peripheral Interventions.

Results provided a thorough investigation of key technical aspects of the coating, including its mechanism of action, systemic, and vascular effects1.

In total, outcomes of the preclinical program were predictive of performance and a very low risk profile for AGENT in clinical use1,2,3.